AAV基因治疗市场按载体血清型、治疗领域、目标组织、适应症类型、基因有效载荷类型、研发阶段、生产类型、最终用户和地区划分

预计到 2025 年，AAV 基因治疗市场价值将达到 34.6 亿美元，预计到 2032 年将达到 169.7 亿美元，2025 年至 2032 年的复合年增长率为 25.5%。

全球 AAV 基因治疗市场是现代医学的一个创新领域，它利用腺结合病毒(AAV) 载体作为先进的递送系统，将治疗基因直接输送到目标细胞中，从而能够治疗各种遗传性和后天性疾病。

由于其优异的安全性、极低的免疫抗原性以及无需整合到宿主基因组中即可实现持续基因表现的能力，AAV 基因疗法已成为一种突破性的治疗方法。

这种创新治疗方法利用了 AAV 载体的独特特性，AAV 是一种天然存在的非致病性病毒，经过广泛的工程改造，消除了其复製能力，同时保留了其将基因转移到多种组织类型中分裂和非分裂细胞的卓越能力。

该市场涵盖多种治疗应用，包括遗传性视网膜疾病、血友病、脊髓性肌肉萎缩症和各种中枢神经系统疾病，许多临床试验显示出令人鼓舞的疗效。随着全球监管机构不断核准基于腺相关病毒（AAV）的基因疗法，以及製药公司加大研发投入，载体工程技术的进步、生产过程的改进以及治疗靶点的拓展，使得AAV基因疗法成为治疗以往无法治癒的遗传疾病的变革性方案，并推动了市场前所未有的增长。

市场动态

全球AAV基因治疗市场受到多种强劲驱动因素的影响，这些因素正推动医疗保健产业的蓬勃发展。主要成长要素是全球遗传性疾病和罕见病患疾病率的不断上升，以及对以往无法治癒的疾病有效治疗方法的迫切需求，从而催生了对创新AAV治疗方案的巨大市场需求。

载体工程领域的重要技术进步，特别是新型AAV衣壳的开发，这些衣壳具有更高的组织特异性和更优的转导效率，极大地拓展了这些治疗方法的治疗潜力和临床应用范围。美国FDA和欧洲药品管理局（EMA）等监管机构建立的支持性法规结构，特别是罕见疾病药物的加速核准程序和孤儿药认定，加速了AAV基因疗法的研发进程和市场准入。

然而，该市场面临着巨大的限制因素，主要是与 AAV 载体生产相关的极高製造成本，这导致治疗成本高昂，限制了患者的获得途径，并给全球医疗保健系统带来了报销方面的挑战。

此外，潜在的安全隐患，例如AAV载体可能引发免疫抗原性反应和基因毒性，仍然是监管方面的障碍，可能会延缓产品核可和市场渗透。儘管存在这些挑战，但随着治疗应用范围从罕见遗传疾病扩展到心血管疾病、神经退化性疾病疾病和眼科疾病等更常见的疾病，以及悬浮细胞培养系统和新型纯化方法等新兴生产技术的出现，市场机会依然巨大。这些技术可望降低生产成本并提高规模化生产能力，最终提升市场可及性和成长潜力。

本报告的主要特点

• 本报告对全球 AAV 基因治疗市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
• 全球 AAV 基因治疗市场的主要企业将根据以下参数进行分析，例如公司概况、产品系列、主要亮点、财务表现和策略。
• 本报告提供的见解将使负责人和公司经营团队能够就未来的产品发布、产品更新、市场扩张和行销策略做出明智的决策。
• 《全球 AAV 基因治疗市场》报告面向该行业的各类相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过用于分析全球 AAV 基因治疗市场的各种策略矩阵，更轻鬆地做出决策。

目录

第一章 分析目标与先决条件

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监管与趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特五力分析
• 企业合併情景
• 产业趋势

4. 全球AAV基因治疗市场依载体血清型划分（2020-2032年）

• AAV9
• AAV2
• AAV5
• AAV8
• AAV1
• 设计的/合成的AAV突变体

5. 全球AAV基因治疗市场依治疗领域划分（2020-2032年）

• 神经系统疾病
• 眼科疾病
• 罕见遗传疾病
• 血液疾病
• 肌肉疾病
• 代谢性疾病
• 心血管疾病
• 瘤
• 其他的

6. 全球AAV基因治疗市场按目标组织划分（2020-2032年）

• 中枢神经系统
• 眼睛/视网膜
• 肝
• 肌肉
• 肺
• 心
• 血液和骨髓

7. 全球AAV基因治疗市场依给药途径划分（2020-2032年）

• 静脉注射
• 鞘内注射
• 脑内给药
• 视网膜下
• 玻璃体内注射
• 肌肉内注射
• 心内给药

8. 全球AAV基因治疗市场依适应症划分（2020-2032年）

• 单基因疾病
• 多基因疾病

9. 全球AAV基因治疗市场依基因酬载类型划分（2020-2032年）

• 基因替换
• 基因静默
• 基因增强

第十章 全球AAV基因治疗市场依发展阶段划分（2020-2032年）

• 临床前阶段
• 第一阶段
• 第二阶段
• 第三阶段

11. 全球AAV基因治疗市场依生产类型划分（2020-2032年）

• 内部生产
• 契约製造（CDMO/CMO）

12. 全球AAV基因治疗市场（依最终用户划分）（2020-2032年）

• 生物製药公司
• 研究机构和学术中心
• 医院和专科诊所
• 其他（CRO）

13. 全球AAV基因治疗市场按地区划分（2020-2032年）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中非

第十四章 竞争格局

• Novartis（AveXis）
• Spark Therapeutics（Roche）
• BioMarin Pharmaceutical
• Sarepta Therapeutics
• uniQure
• Regenxbio
• Audentes Therapeutics（Astellas）
• Voyager Therapeutics
• MeiraGTx
• Asklepios BioPharmaceutical（AskBio-Bayer）
• Krystal Biotech
• Genethon
• BridgeBio Gene Therapy
• Passage Bio
• Solid Biosciences

第十五章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map (COM)

第十六章 参考文献与分析方法

• 参考
• 分析方法
• 关于 Coherent Market Insights

AAV Gene Therapy Market is estimated to be valued at USD 3.46 Bn in 2025 and is expected to reach USD 16.97 Bn by 2032, growing at a compound annual growth rate (CAGR) of 25.5% from 2025 to 2032.

The global AAV gene therapy market represents a revolutionary frontier in modern medicine, utilizing Adeno-Associated Virus (AAV) vectors as sophisticated delivery systems to transport therapeutic genes directly into target cells for treating various genetic disorders and acquired diseases.

AAV gene therapy has emerged as a groundbreaking therapeutic approach due to its exceptional safety profile, minimal immunogenicity, and ability to achieve long-lasting gene expression without integrating into the host genome.

This innovative treatment modality leverages the unique characteristics of AAV vectors, which are naturally occurring, non-pathogenic viruses that have been extensively engineered to remove their replicative capacity while retaining their remarkable ability to transduce both dividing and non-dividing cells across multiple tissue types.

The market encompasses a diverse range of therapeutic applications including inherited retinal diseases, hemophilia, spinal muscular atrophy, and various central nervous system disorders, with numerous clinical trials demonstrating promising efficacy outcomes. As regulatory agencies worldwide continue to approve AAV-based gene therapies and pharmaceutical companies intensify their research and development efforts, the market is experiencing unprecedented growth driven by technological advancements in vector engineering, improved manufacturing processes, and expanding therapeutic targets that collectively position AAV gene therapy as a transformative solution for previously untreatable genetic conditions.

Market Dynamics

The global AAV gene therapy market is propelled by several compelling drivers that collectively fuel its robust expansion across the healthcare landscape. The primary growth catalyst stems from the increasing prevalence of genetic disorders and rare diseases worldwide, coupled with the urgent unmet medical need for effective treatments in conditions previously deemed incurable, creating substantial market demand for innovative AAV-based therapeutic solutions.

Significant technological advancements in vector engineering, including the development of novel AAV capsids with enhanced tissue specificity and improved transduction efficiency, have dramatically expanded the therapeutic potential and clinical applicability of these treatments. Supportive regulatory frameworks established by agencies such as the U.S. FDA and EMA, including expedited approval pathways for rare disease treatments and orphan drug designations, have accelerated the development timeline and market entry for AAV gene therapies.

However, the market faces notable restraints primarily centered around the exceptionally high manufacturing costs associated with AAV vector production, which translates into substantial treatment expenses that limit patient accessibility and create reimbursement challenges for healthcare systems globally.

Additionally, potential safety concerns including immunogenic responses to AAV vectors and the risk of genotoxicity continue to pose regulatory hurdles that may delay product approvals and market penetration. Despite these challenges, the market presents tremendous opportunities driven by expanding therapeutic applications beyond rare genetic diseases into more prevalent conditions such as cardiovascular diseases, neurodegenerative disorders, and ophthalmologic conditions, while emerging manufacturing technologies including suspension cell culture systems and novel purification methods promise to reduce production costs and improve scalability, ultimately enhancing market accessibility and growth potential.

Key Features of the Study

• This report provides in-depth analysis of the global AAV gene therapy market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global AAV gene therapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Novartis (AveXis), Spark Therapeutics (Roche), BioMarin Pharmaceutical, Sarepta Therapeutics, uniQure, Regenxbio, Audentes Therapeutics (Astellas), Voyager Therapeutics, MeiraGTx, Asklepios BioPharmaceutical (AskBio - Bayer), Krystal Biotech, Genethon, BridgeBio Gene Therapy, Passage Bio, and Solid Biosciences
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global AAV gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global AAV gene therapy market

Market Segmentation

• Vector Serotype Insights (Revenue, USD Bn, 2020 - 2032)
  • AAV9
  • AAV2
  • AAV5
  • AAV8
  • AAV1
  • Engineered/Synthetic AAV Variants
• Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
  • Neurological Disorders
  • Ophthalmic Disorders
  • Rare Genetic Disorders
  • Hematological Disorders
  • Muscular Disorders
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Oncology
  • Others
• Target Tissue Insights (Revenue, USD Bn, 2020 - 2032)
  • Central Nervous System
  • Eye/Retina
  • Liver
  • Muscle
  • Lung
  • Heart
  • Blood/Bone Marrow
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Intravenous
  • Intrathecal
  • Intracerebral
  • Subretinal
  • Intravitreal
  • Intramuscular
  • Intracardiac
• Indication Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Monogenic Disorders
  • Polygenic Disorders
• Gene Payload Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Gene Replacement
  • Gene Silencing
  • Gene Augmentation
• Development Stage Insights (Revenue, USD Bn, 2020 - 2032)
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
• Manufacturing Type Insights (Revenue, USD Bn, 2020 - 2032)
  • In-house Manufacturing
  • Contract Manufacturing (CDMO/CMO)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Biopharmaceutical Companies
  • Research Institutes and Academic Centers
  • Hospitals and Specialty Clinics
  • Others (CROs)
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Novartis (AveXis)
  • Spark Therapeutics (Roche)
  • BioMarin Pharmaceutical
  • Sarepta Therapeutics
  • uniQure
  • Regenxbio
  • Audentes Therapeutics (Astellas)
  • Voyager Therapeutics
  • MeiraGTx
  • Asklepios BioPharmaceutical (AskBio - Bayer)
  • Krystal Biotech
  • Genethon
  • BridgeBio Gene Therapy
  • Passage Bio
  • Solid Biosciences

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global AAV Gene Therapy Market, By Vector Serotype
  • Global AAV Gene Therapy Market, By Therapeutic Area
  • Global AAV Gene Therapy Market, By Target Tissue
  • Global AAV Gene Therapy Market, By Route of Administration
  • Global AAV Gene Therapy Market, By Indication Type
  • Global AAV Gene Therapy Market, By Gene Payload Type
  • Global AAV Gene Therapy Market, By Development Stage
  • Global AAV Gene Therapy Market, By Manufacturing Type
  • Global AAV Gene Therapy Market, By End User
  • Global AAV Gene Therapy Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global AAV Gene Therapy Market, By Vector Serotype, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• AAV9
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• AAV2
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• AAV5
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• AAV8
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• AAV1
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Engineered/Synthetic AAV Variants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global AAV Gene Therapy Market, By Therapeutic Area, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Neurological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Ophthalmic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Rare Genetic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hematological Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Muscular Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Metabolic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cardiovascular Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Oncology
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global AAV Gene Therapy Market, By Target Tissue, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Central Nervous System
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Eye/Retina
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Liver
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Muscle
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Lung
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Heart
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Blood/Bone Marrow
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global AAV Gene Therapy Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intrathecal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intracerebral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Subretinal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intravitreal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intramuscular
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intracardiac
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global AAV Gene Therapy Market, By Indication Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Monogenic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Polygenic Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global AAV Gene Therapy Market, By Gene Payload Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Gene Replacement
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Gene Silencing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Gene Augmentation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global AAV Gene Therapy Market, By Development Stage, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Preclinical
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phase I
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phase II
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phase III
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global AAV Gene Therapy Market, By Manufacturing Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• In-house Manufacturing
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Contract Manufacturing (CDMO/CMO)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global AAV Gene Therapy Market, By End User, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Biopharmaceutical Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Research Institutes and Academic Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Hospitals and Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others (CROs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global AAV Gene Therapy Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Vector Serotype, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Target Tissue, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Indication Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Gene Payload Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Development Stage, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Manufacturing Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

14. Competitive Landscape

• Novartis (AveXis)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Spark Therapeutics (Roche)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BioMarin Pharmaceutical
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Sarepta Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• uniQure
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Regenxbio
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Audentes Therapeutics (Astellas)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Voyager Therapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• MeiraGTx
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Asklepios BioPharmaceutical (AskBio - Bayer)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Krystal Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Genethon
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• BridgeBio Gene Therapy
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Passage Bio
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Solid Biosciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

15. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

16. References and Research Methodology

• References
• Research Methodology
• About us